Immunosuppressive T-cell antibody induction for heart transplant recipients

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 12, 2013, Pages

  Penninga, Luit ^a   Møller, Christian H ^a   Gustafsson, Finn ^b   Gluud, Christian ^a   Steinbrüchel, Daniel A ^a  

^a Rigshospitalet   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BB 10; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORINE; DACLIZUMAB; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; INOLIMOMAB; INOLIMOMAB PLUS MONOCLONAL ANTIBODY BB 10; INTERLEUKIN 2 RECEPTOR ANTAGONIST; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL T LYMPHOCYTE ANTIBODY; MYCOPHENOLATE MOFETIL; OKT 3; PLACEBO; POLYCLONAL ANTIBODY; STEROID; T LYMPHOCYTE ANTIBODY; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALGANCICLOVIR; HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 2 RECEPTOR;

ACUTE GRAFT REJECTION; ANAPHYLAXIS; ANTIBODY INDUCTION; ATHEROSCLEROSIS; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CREATININE BLOOD LEVEL; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIALYSIS; DIARRHEA; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FEASIBILITY STUDY; FEVER; GRAFT ATHEROSCLEROSIS; GRAFT FAILURE; GRAFT SURVIVAL; HEADACHE; HEART TRANSPLANTATION; HEMATOLOGIC DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; IMMUNOLOGICAL PROCEDURES; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LUNG EDEMA; LYMPHOCYTIC MENINGITIS; MALIGNANT NEOPLASM; MENINGITIS; META ANALYSIS; MORTALITY; NEPHROTOXICITY; NEUROLOGIC DISEASE; PLACEBO EFFECT; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; RASH; REVIEW; SERUM SICKNESS; SYSTEMATIC REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING; DRUG ANTAGONISM; GRAFT REJECTION; IMMUNOLOGY; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; MUROMONAB-CD3; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84897576002     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008842.pub2     Document Type: Review

References (108)

1. Balk AH, Meeter K, Simoons ML, Brouwer RM, Zondervan PE, Mochtar B, et al. Polyclonal versus monoclonal rejection prophylaxis after heart transplantation: a randomised study. Transplantation International 1992;5 Suppl 1:S476-9.
2. Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke EM, Groff BD, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. New England Journal of Medicine 2000;342(9):613-9.
3. Bolling SF, Stirling MC, Miska P, Deeb GM. Comparison of polyclonal antibody sera for early prophylaxis following cardiac transplantation. Journal of Surgical Research 1989;47(4):292-6.
4. Bonaros N, Dunkler D, Kocher A, Imhof M, Grimm M, Zuckermann A, et al.Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation. Journal of Heart and Lung Transplantation 2006;25(9):1154-63.
5. Carrier M, Leblanc MH, Perrault LP, White M, Doyle D, Beaudoin D, et al. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. Journal of Heart and Lung Transplantation 2007;26(3):258-63.
6. Costanzo-Nordin MR, O'Sullivan EJ, Johnson MR, Winters GL, Pifarre R, Radvany R, et al. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation. Journal of Heart Transplantation 1990;9(3 Pt 2):306-15.
7. De Santo LS, Della Corte A, Romano G, Amarelli C, Onorati F, Torella M, et al. Midterm results of a prospective randomized comparison of two different rabbit-antithymocyte globulin induction therapies after heart transplantation. Transplantation Proceedings 2004;36(3):631-7.
8. Faggian G, Forni A, Milano AD, Chiominto B, Walpoth BH, Scarabelli T, et al. Antithymocyte globulin induction therapy in heart transplantation: prospective randomized study of high vs standard dosage. Transplantation Proceedings 2010;42(9):3679-87.
9. Forni A, Faggian G, Chiominto B, Mazzucco A. Anti rejection prophylaxis using ATG-Fresenius S after heart transplantation - long-term clinical results of a prospective, randomised trial. Transplant International 2007;20:116.
10. Hershberger RE, Starling RC, Eisen HJ, Bergh CH, Kormos RL, Love RB, et al. Daclizumab to prevent rejection after cardiac transplantation. New England Journal of Medicine 2005;352(26):2705-13.
11. Ippoliti G, Negri M, Abelli P, Rovati B, Di Franco L, Grossi P, et al. Preoperative prophylactic OKT3 vs RATG. A randomized clinical study in heart transplant patients. Transplantation Proceedings 1991;23(4):2272-4.
12. Origlia C, Ippoliti G, Martinelli L, Goggi C, Abelli P, Negri M, et al. A randomized clinical-study of preoperative administration of Okt3 vs Ratg in heart transplanted patients treated with Sandimmun. Transplantation and Clinical Immunology. 1991; Vol. 16:250.
13. Kobashigawa JA, Stevenson LW, Brownfield E, Moriguchi JD, Kawata N, Hamilton M, et al. Does short-course induction with OKT3 improve outcome after heart transplantation? A randomized trial. Journal of Heart and Lung Transplantation 1993;12(2):205-8.
14. Griffith BP, Kormos RL, Armitage JM, Dummer JS, Hardesty RL. Comparative trial of immunoprophylaxis with RATG versus OKT3. Journal of Heart Transplantation 1990;9(3 Pt 2):301-5.
15. Kormos RL, Armitage JM, Dummer JS, Miyamoto Y, Griffith BP, Hardesty RL. Optimal perioperative immunosuppression in cardiac transplantation using rabbit antithymocyte globulin. Transplantation 1990;49(2):306-11.
16. Kormos RL, Herlan DB, Armitage JM, Stein K, Kaufman C, Zeevi A, et al. Monoclonal versus polyclonal antibody therapy for prophylaxis against rejection after heart transplantation. Journal of Heart Transplantation 1990;9(1):1-9.
17. Macdonald PS, Mundy J, Keogh AM, Chang VP, Spratt PM. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation--increased morbidity with OKT3. Transplantation 1993;55(1):110-6.
18. Boissonnat P, Sebbag L, French Heart Nausicaa Study Grp. Less infectious deaths with basiliximab (Simulect (R)) over antihymocyte globulin (Thymoglobuline (R)) induction therapy in heart transplantation: Results of nausicaa, a national multicentre prospective randomized study. 2005; Vol. 5:386.
19. Mattei MF, Boissonnat P, Redonnet M, Gandjbakhch I, Bandini AM, Dorent R, et al. Improved safety of basiliximab (Simulect (R)) over antithymocyte globulin (Thymoglobulin (R)) induction therapy in heart transplantation. Journal of Heart and Lung Transplantation 2005;24(2):63.
20. Mattei MF, Redonnet M, Gandjbakhch I, Bandini AM, Billes A, Epailly E, et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. Journal of Heart and Lung Transplantation 2007;26(7):693-9.
21. Mehra MR, Zucker MJ, Wagoner L, Michler R, Boehmer J, Kovarik J, et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. Journal of Heart and Lung Transplantation 2005;24(9):1297-304.
22. Menkis AH, Powell AM, Novick RJ, McKenzie FN, Kostuk WJ, Pflugfelder PW, et al. A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts. Journal of Heart and Lung Transplantation 1992;11(3 Pt 1):569-76.
23. Mullen JC, Dueck A, Bentely MJ, Modry DL, Wang SH, Burton JR, et al. A randomized control trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation. Journal of Heart and Lung Transplantation 2005;24(2):143.
24. Schnetzler B, Leger P, Volp A, Dorent R, Pavie A, Gandjbakhch I. A prospective randomized controlled study on the efficacy and tolerance of two antilymphocytic globulins in the prevention of rejection in first-heart transplant recipients. Transplant International 2002;15(6):317-25.
25. Segovia J, Rodriguez-Lambert JL, Crespo-Leiro MG, Almenar L, Roig E, Gomez-Sanchez MA, et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 2006;81(11):1542-8.
26. Wabbijn M, Balk AH, van Domburg RT, Vantrimpont PJ, van Riemsdijk I, Baan CC, et al.Ten-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptor. Experimental and Clinical Transplantation 2004;2(1):201-7.
27. van Gelder T, Baan CC, Balk AH, Knoop CJ, Holweg CT, van der Meer P, et al. Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans. Transplantation 1998;65(3):405-10.
28. van Gelder T, Balk AH, Jonkman FA, Zietse R, Zondervan P, Hesse CJ, et al. A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation. Transplantation 1996;62(1):51-5.
29. van Gelder T, Mulder AH, Balk AH, Mochtar B, Hesse CJ, Baan CC, et al. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients. Journal of Heart and Lung Transplantation 1995;14(2):346-50.
30. van Gelder T, Wabbijn M, van Domburg R, Vantrimpont P, Maat L, Baan C, et al. A randomised, double-blind, placebo controlled trial of anti interleukin-2 receptor monoclonal antibody (daclizumab) induction therapy after heart transplantation. American Journal of Transplantation 2004;4:450.
31. Wollenek G, Laufer G, Laczkovics A, Buxbaum P, Kober I. Comparison of a monoclonal anti-T cell antibody vs ATG as prophylaxis after heart transplantation. Transplantation Proceedings 1989;21(1 Pt 3):2499-501.
32. Adamson R, Obispo E, Dychter S, Dembitsky W, Moreno-Cabral R, Jaski B, et al.Long-term outcome with the use of OKT3 induction therapy in heart transplant patients: a single-center experience. Transplantation Proceedings 1998;30(4):1107-9.
33. Almenar L, Garcia-Palomar C, Martinez-Dolz L, Chamorro C, Moro J, Zorio E, et al. Influence of induction therapy on rejection and survival in heart transplantation. Transplantation Proceedings 2005;37(9):4024-7.
34. Carlsen J, Johansen M, Boesgaard S, Andersen CB, Arendrup H, Aldershvile J, et al. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection. Journal of Heart and Lung Transplantation 2005;24(3):296-302.
35. Chien NC, Lin FL, Chou NK, Hsu RB, Wang SS, Chu SH, et al. Rabbit antithymocyte globulin induction immunosuppression in heart transplantation. Transplantation Proceedings 2000;32(7):2380-2.
36. Chin C, Pittson S, Luikart H, Bernstein D, Robbins R, Reitz B, et al. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Transplantation 2005;80(4):477-81.
37. Chou NK, Wang SS, Chen YS, Yu HY, Chi NH, Wang CH, et al. Induction immunosuppression with basiliximab in heart transplantation. Transplantation Proceedings 2008;40(8):2623-5.
38. Costanzo-Nordin MR, O'Sullivan EJ, Hubbell EA, Zucker MJ, Pifarre R, McManus BM, et al.Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience. Journal of Heart Transplantation 1989;8(4):288-95.
39. Delgado DH, Miriuka SG, Cusimano RJ, Feindel C, Rao V, Ross HJ. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction. Journal of Heart and Lung Transplantation 2005;24(2):166-9.
40. Flaman F, Zieroth S, Rao V, Ross H, Delgado DH. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. Journal of Heart and Lung Transplantation 2006;25(11):1358-62.
41. Hegewald MG, O'Connell JB, Renlund DG, Lee HR, Burton NA, Karwande SV, et al.OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation. Journal of Heart Transplantation. UNITED STATES, 1989; Vol. 8, issue 4:303-9.
42. Kirklin JK, Bourge RC, White-Williams C, Naftel DC, Thomas FT, Thomas JM, et al. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3. Journal of Thorac and Cardiovascular Surgery 1990;99(4):716-24.
43. Koch A, Daniel V, Dengler TJ, Schnabel PA, Hagl S, Sack FU. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat). Journal of Heart and Lung Transplantation 2005;24(6):708-13.
44. Laufer G, Laczkovics A, Wollenek G, Schreiner W, Sochor H, Holzinger C, et al. Impacts of low-dose steroids and prophylactic monoclonal versus polyclonal antibodies on acute rejection in cyclosporine- and azathioprine-immunosuppressed cardiac allografts. Journal of Heart Transplantation 1989;8(3):253-61.
45. Petrikovits E, Bedanova H, Necas J, Studenik P, Cerny J. Daclizumab in the induction phase of immunosuppression in heart transplant recipients. Annals of Transplantation 2005;10(3):5-10.
46. Pham SM, Bednar BM, Panos A, Bauerlein EJ, Jimenez F, Rosenkrantz E, et al. A randomized study using humanized monoclonal antibody against Cd52 (Campath-1h) and tacrolimus in heart transplant recipients. Journal of Heart and Lung Transplantation 2010;29(2):134.
47. Renlund DG, O'Connell JB, Gilbert EM, Hammond ME, Burton NA, Jones KW, et al. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3. Transplantation 1989;47(4):599-605.
48. Rosenberg PB, Vriesendorp AE, Drazner MH, Dries DL, Kaiser PA, Hynan LS, et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. Journal of Heart and Lung Transplantation 2005;24:1327-31.
49. Starnes VA, Oyer PE, Stinson EB, Dein JR, Shumway NE. Prophylactic OKT3 used as induction therapy for heart transplantation. Circulation 1989;80(5 Pt 2):III79-83.
50. Teuteberg JJ, Shullo MA, Zomak R, Toyoda Y, McNamara DM, Bermudez C, et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. American Journal of Transplantation 2010;10(2):382-8.
51. Yamani MH, Taylor DO, Czerr J, Haire C, Kring R, Zhou L, et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. Clinical Transplantation 2008;22(1):76-81.
52. Zakliczynski MW, Nozynski J, Maruszewski M, Zembala M. Thymoglobuline administered electively early after heart transplantation may protect myocardial hypertrophy (Abstract). American Journal of Transplantation. American Transplant Congress, Seattle [United States] 21-25 May 2005. 2005; Vol. 5, issue Suppl 11:171.
53. Zuckermann AO, Grimm M, Czerny M, Ofner P, Ullrich R, Ploner M, et al. Improved long-term results with thymoglobuline induction therapy after cardiac transplantation: a comparison of two different rabbit-antithymocyte globulines. Transplantation 2000;69(9):1890-8.
54. Zuckermann A, Dunkler D, Deviatko E, Bodhjalian A, Czerny M, Ankersmit J, et al.Long-term survival (>10 years) of patients >60 years with induction therapy after cardiac transplantation. European Journal of Cardiothoracic Surgery 2003;24(2):283-91.
55. Cantarovich M. Renal protective strategies in heart transplant patients. Current Opinion in Cardiology 2007;22(2):133-8.
56. Chatenoud L. The long and winding road towards induction of allograft tolerance in the clinic. Transplant International 2008;21:725-7.
57. Chen W, Zhang L. Regulatory T-cell subsets and their roles in transplantation tolerance. Current Opinion in Organ Transplantation 2006;11(4):373-8.
58. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non-randomised intervention studies. Health Technology Assessment 2003;7(27):1-173.
59. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
60. El-Hamamsy I, Stevens LM, Carrier M, Pelletier G, White M, Tremblay F, et al. Incidence and prognosis of cancer following heart transplantation using RATG induction therapy. Transplant International 2005;18(11):1280-5.
61. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clinical Transplantation 2008;22(1):1-15.
62. Gluud LL. Bias in clinical intervention research. American Journal of Epidemiology 2006;163:493-501.
63. Groetzner J, Wahlers T. Calcineurin inhibitor-free immunosuppression after heart transplantation: can chronic side effects be avoided?. Current Opinion in Organ Transplantation 2005;10(4):360-3.
64. Hauptman PJ, Mehra MR. It is time to stop ignoring malignancy in heart transplantation: a call to arms. Journal of Heart and Lung Transplantation 2005;24:1111-3.
65. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
66. Higgins R, Kirklin JK, Brown RN, Rayburn BK, Wagoner L, Oren R, et al. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?. Journal of Heart and Lung Transplantation 2005;24(4):392-400.
67. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
68. ICH-GCP 1996 International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Guideline for Good Clinical Practice. E6 (R1). ICH Harmonised Tripartite Guideline 1996. http://ichgcp.net (accessed 2 September 2010).
69. Keus F, Wetterslev J, Gluud C, Gooszen HG, van Laarhoven CJ. Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials. American Journal of Gastroenterology 2009;104(3):546-51.
70. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135:982-9.
71. Kobashigawa J, David K, Morris J, Chu AH, Steffen BJ, Gotz VP, et al. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. Transplantation Proceedings 2005;37(2):1333-9.
72. Kobashigawa JA, Patel JK. Immunosuppression for heart transplantation: where are we now?. Nature Clinical Practice Cardiovascular Medicine 2006;3(4):203-12.
73. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation--how much of the promise has been realized?. Nature Medicine 2005;11:605-13.
74. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. The Cochrane Collaboration, Available from www.cochrane-handbook.org.
75. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20:641-54.
76. Mallinger R, Chevtchik O, Zuckermann A, Jucewicz M, Moidl R, Kocher A, et al. Development and spectrum of PTLD in 691 cardiac transplant recipients (Htx) receiving induction therapy. Journal of Heart and Lung Transplantation 1999;19(1):77 (abstract 174).
77. United States Cochrane Center. Master list of journals being searched. http://apps1.jhsph.edu/cochrane/masterlist.asp (accessed May 2009).
78. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
79. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009;62:1006-12.
80. Mueller XM. Drug immunosuppression therapy for adult heart transplantation. Part 2: clinical applications and results. Annals of Thoracic Surgery 2004;77:363-71.
81. O'Neill JOT. Immunosuppression for cardiac transplantation - the past, present and future. Transplantation Proceedings 2004;36(2 SUPPL):309S-13S.
82. Oaks TE, Wannenberg T, Close SA, Tuttle LE, Kon ND. Steroid-free maintenance immunosuppression after heart transplantation. Annals of Thoracic Surgery 2001;72:102-6.
83. Penninga L, Moller CH, Gustafsson F, Steinbruchel DA, Gluud C. Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. European Journal of Clinical Pharmacology 2010;66(12):1177-87.
84. Penninga L, Møller CH, Penninga EI, Iversen M, Gluud C, Steinbrüchel DA. Antibody induction for lung transplant recipients. Cochrane Database of Systematic Reviews 2011, (1):Art. No.: CD008927. DOI: 10.1002/14651858.CD008927.
85. Penninga L, Wettergren A, Wilson CH, Chan AW, Steinbrüchel DA, Gluud C. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients. Cochrane Database of Systematic Reviews 2012. [DOI: 10.1002/14651858.CD007341.pub2]
86. Peraira JR, Segovia J, Fuertes B, Fernandez JA, Escudier JM, Salas C, et al. Current induction immunosuppression and post-heart transplant lymphoproliferative disorders. Transplantation Proceedings 2003;35(5):2009-10.
87. Potter B, Giannetti N, Cecere R, Cantarovich M. Long-term calcineurin inhibitor "holiday" using daclizumab in a heart transplant patient with acute renal dysfunction. Journal of Heart and Lung Transplantation 2005;24:1126-8.
88. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
89. Rinaldi M, Pellegrini C, D'Armini AM, Aiello M, Negri M, Arbustini E, et al. Neoplastic disease after heart transplantation: single center experience. European.Journal of Cardiothoracic Surgery 2001;19(5):696-701.
90. Royle P, Waugh N. Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system. Health Technology Assessment 2003;7:1-51.
91. Savovic J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al. Influence of reported study design characteristics on Intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
92. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
93. Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report-2012. Journal of Heart and Lung Transplantation. 2012;31(10):1052-64.
94. Stevens LM, El-Hamamsy I, Leblanc M, Perrault LP, Pellerin M, Bouchard D, et al. Continuous renal replacement therapy after heart transplantation. Canadian Journal of Cardiology 2004;20(6):619-23.
95. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. Journal of Heart and Lung Transplantation 2005;24:1710-20.
96. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 2004;23:1351-75.
97. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. New England Journal of Medicine 1990;323(25):1723-8.
98. Taylor DO, Stehlik J, Edwards LB, Aurora P, Christie JD, Dobbels F, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult heart transplant report-2009. Journal of Heart and Lung Transplantation 2009;28:1007-22.
99. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted?. Statistics in Medicine 2002;21:1559-73.
100. Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study. PLoS One 2011;6(10):e25491.
101. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark 2011:1-115.
102. Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C, Thorlund K. Trial Sequential Analysis Programme. 0.9 beta 2012.
103. Uber PA, Mehra MR. Induction therapy in heart transplantation: is there a role?. Journal of Heart and Lung Transplantation 2007;26:205-9.
104. Webster AC, Ruster LP, McGee R, Matheson SL, Higgins GY, Willis NS, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD003897.pub3]
105. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61:64-75.
106. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86.
107. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Edition) 2008;336:601-5.
108. Zuppan CW, Wells LM, Kerstetter JC, Johnston JK, Bailey LL, Chinnock RE. Cause of death in pediatric and infant heart transplant recipients: review of a 20-year, single-institution cohort. Journal of Heart and Lung Transplantation 2009;28:579-84.